Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model.

Autor: Seo Y, Gustafson WC, Dannoon SF, Nekritz EA, Lee CL, Murphy ST, Vanbrocklin HF, Hernandez-Pampaloni M, Haas-Kogan DA, Weiss WA, Matthay KK, Seo, Youngho, Gustafson, W Clay, Dannoon, Shorouk F, Nekritz, Erin A, Lee, Chang-Lae, Murphy, Stephanie T, VanBrocklin, Henry F, Hernandez-Pampaloni, Miguel, Haas-Kogan, Daphne A

Publikováno v: Molecular Imaging & Biology; Dec2012, Vol. 14 Issue 6, p735-742, 8p

miR-424/503 modulates Wnt/β-catenin signaling in the mammary epithelium by targeting LRP6.

Autor: Nekritz EA; Graduate School, Department of Pathology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA., Rodriguez-Barrueco R; Molecular Mechanisms and Experimental Therapy in Oncology-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Anatomy Unit, Department of Pathology and Experimental Therapy, School of Medicine, University of Barcelona (UB), L'Hospitalet de Llobregat, Barcelona, Spain., Yan KK; Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA., Davis ML; Molecular Mechanisms and Experimental Therapy in Oncology-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Department of Pathology, Duke University School of Medicine, Durham, NC, USA., Werner RL; Graduate School, Department of Pathology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA., Devis-Jauregui L; Molecular Mechanisms and Experimental Therapy in Oncology-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain., Mukhopadhyay P; Graduate School, Department of Pathology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA., Yu J; Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA., Llobet-Navas D; Molecular Mechanisms and Experimental Therapy in Oncology-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain., Silva J; Graduate School, Department of Pathology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.

Publikováno v: EMBO reports [EMBO Rep] 2021 Dec 06; Vol. 22 (12), pp. e53201. Date of Electronic Publication: 2021 Oct 11.

Drugging MYCN through an allosteric transition in Aurora kinase A.

Autor: Gustafson WC; Department of Pediatrics, UCSF Benioff Children's Hospital, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA., Meyerowitz JG; Departments of Neurology and Neurological Surgery, University of California, San Francisco, San Francisco, CA 94158, USA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA., Nekritz EA; Department of Pediatrics, UCSF Benioff Children's Hospital, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA., Chen J; Departments of Neurology and Neurological Surgery, University of California, San Francisco, San Francisco, CA 94158, USA., Benes C; Massachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02114, USA., Charron E; Department of Pediatrics, UCSF Benioff Children's Hospital, University of California, San Francisco, San Francisco, CA 94158, USA; Departments of Neurology and Neurological Surgery, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA., Simonds EF; Departments of Neurology and Neurological Surgery, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA., Seeger R; Division of Hematology/Oncology, Children's Hospital Los Angeles, 4650 Sunset Boulevard, Mailstop #57, Los Angeles, CA 90027, USA., Matthay KK; Department of Pediatrics, UCSF Benioff Children's Hospital, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA., Hertz NT; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA., Eilers M; Theodor Boveri Institute, Biocenter, University of Wurzburg, Am Hubland, 97074 Würzburg, Germany., Shokat KM; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, CA 94158, USA., Weiss WA; Department of Pediatrics, UCSF Benioff Children's Hospital, University of California, San Francisco, San Francisco, CA 94158, USA; Departments of Neurology and Neurological Surgery, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address: waweiss@gmail.com.

Publikováno v: Cancer cell [Cancer Cell] 2014 Sep 08; Vol. 26 (3), pp. 414-427. Date of Electronic Publication: 2014 Aug 28.